News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium

EP. 1: Current Treatment Landscape for HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

EP. 2: Prognostic Tools for Early-Stage HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

EP. 3: Updated Data for Metastatic HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS

Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles

Dr Marvin-Peek on the Significance of Efficacy Data for Azacitidine/Ivosidenib/Venetoclax in IDH1-Mutated AML